Progressive Reports April 2023 Results

The Progressive Corporation (NYSE:PGR) today reported the following results for April 2023:   April (millions, except per share amounts and ratios;

The Progressive Corporation (NYSE:PGR) today reported the following results for April 2023:
 

April
(millions, except per share amounts and ratios; unaudited)  2023  2022 Change
Net premiums written $ 6,075.4 $ 4,820.7 26 %
Net premiums earned $ 5,458.8 $ 4,614.1 18 %
Net income (loss) $ 196.3 $ (198.3 ) (199 )  %
Per share available to common shareholders $ 0.33 $ (0.34 ) (196 )  %
Total pretax net realized gains (losses) on securities $ 18.4 $ (524.5 ) (104 )  %
Combined ratio 97.9 95.5 2.4 pts.
Average equivalent common shares 587.1 584.3 0 %

 

April
(thousands; unaudited)
 
2023 2022 Change
Policies in Force
Personal Lines
Agency – auto 8,337.1 7,702.3 8 %
Direct – auto 11,191.1 9,537.7 17 %
Total personal auto 19,528.2 17,240.0 13 %
Total special lines 5,715.9 5,392.0 6 %
Total Personal Lines 25,244.1 22,632.0 12 %
Total Commercial Lines 1,085.9 1,012.3 7 %
Total Property business 2,939.4 2,812.8 5 %
Companywide Total 29,269.4 26,457.1 11 %

See Progressive’s complete monthly earnings release, including the “Monthly Commentary,” for additional information.

Total
0
Shares
Related Posts
Read More

Understanding How Stablecoins Have Fared In The Crypto Bear Phase

Cryptocurrencies have long been considered a hedge against inflation and a better alternative to fiat currencies that are susceptible to devaluation concerns. Most cryptocurrencies have significantly underperformed benchmark stock market indices due to liquidity pressures brought about by the tightening of monetary policy by leading central banks such as the U.S. Federal Reserve.

$DAI

Read More

Mesoblast Says Resumbits Biologic License Application To FDA For Remestemcel-L In Children With With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

Validation of Remestemcel-L Potency Assay used in the Phase 3 Trial which Measures In-Vivo Activity based on Mechanism of Action Assay Identifies High-Potency Product Lots Associated with Enhanced Survival New Data Show that Remestemcel-L Improves Inflammatory Biomarkers and Survival in Children at Highest Risk of Mortality

MESO